Show side menu

HEXOVAC: Exosome-deived quasi-enveloped virus particles as candidate for novel hepatitis A and E vaccines.

Starting date: 21/06/2019 End date: 20/06/2022
Programme: Animal health

Financing entities:

The present proposal addresses four main objectives:
  1. Development of methodologies to improve the production and purification of a fast-growing HAV strain in cell cultures used in vaccine manufacturing. Antigenic characterization of naked and pseudo-enveloped-particles.
  2. Characterization of the immunogenic properties in mice of HAV pseudo-enveloped-particles compared with nakedparticles.
  3. Evaluation of the protective effect generated by a potential vaccine based on pseudo-enveloped particles, compared to naked-particles, in a mouse model of hepatitis A infection.
  4. Characterization of the immunogenic properties in pigs of HAV pseudo-enveloped-particles compared with nakedparticles.